The benzodiazepines: anxiolytic and withdrawal effects

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Benzodiazepine withdrawal and inverse agonists induce anxiety.
• Chronic benzodiazepine treatment leads to decreased GABAA receptor sensitivity and tolerance.
• Benzodiazepine inverse agonists exhibit complex effects on convulsive and anxiolytic behaviors.

Purpose of the Study:

• To investigate the effects of flumazenil and verapamil on benzodiazepine withdrawal-induced anxiety.
• To explore the role of GABAA receptor sensitivity in benzodiazepine tolerance and withdrawal.
• To examine the potential of flumazenil to 'reset' the benzodiazepine receptor complex.

Main Methods:

• Utilizing animal models to measure anxiety during benzodiazepine withdrawal.
• Administering flumazenil 24 hours prior to measurements to assess its preventative effects.
• Investigating the impact of concurrent chronic verapamil treatment with chronic benzodiazepine administration.

Main Results:

• Flumazenil administration prevented GABAA receptor sensitivity changes and benzodiazepine tolerance.
• Flumazenil also prevented anxiety and decreased seizure threshold during benzodiazepine withdrawal.
• Acute flumazenil reduced anxiety during ethanol withdrawal, and chronic verapamil prevented anxiety from chronic benzodiazepine treatment.

Conclusions:

• Flumazenil may induce a prolonged 'resetting' of the benzodiazepine receptor complex.
• Flumazenil is effective in mitigating anxiety associated with benzodiazepine withdrawal and ethanol withdrawal.
• Verapamil offers a potential therapeutic strategy for preventing anxiety linked to chronic benzodiazepine use.